Literature DB >> 24837184

Mesenchymal-like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial-like counterparts.

Arkadeep Sinha1, David Cherba2, Heather Bartlam2, Elizabeth Lenkiewicz3, Lisa Evers3, Michael T Barrett3, Brian B Haab4.   

Abstract

The aggressiveness of pancreatic cancer is associated with the acquisition of mesenchymal characteristics by a subset of pancreatic cancer cells. The factors driving the development of this subset are not well understood. In this study, we tested the hypothesis that acquisition of a mesenchymal phenotype occurs selectively in tumor cells that harbor specific enabling genetic alterations. We obtained whole-genome comparative genomic hybridization (CGH) measurements on pancreatic cancer cell lines that have either an epithelial-like (17 cell lines) or a mesenchymal-like (9 cell lines) phenotype in vitro. The total amounts of amplifications and deletions were equivalent between the epithelial and mesenchymal groups, but 20 genes showed a major difference between the groups in prevalence of alterations. All 20 alterations (18 deletions and 2 amplifications) were more prevalent in the mesenchymal group, confirming the advanced nature of this cellular subtype. CDKN2A was altered in more than 50% of both groups, but co-deletions in neighboring genes, and concomitant loss of gene expression, were more prevalent in the mesenchymal group, suggesting that the size of the loss around CDKN2A affects cell phenotype. Whole-genome CGH on 11 primary cancer tissues revealed that the 20 genes were altered at a higher prevalence (up to 55% of the cases for certain genes) than randomly selected sets of 20 genes, with the same direction of alteration as in the cell lines. These findings support the concept that specific genetic alterations enable phenotype plasticity and provide promising candidate genes for further research.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cellular plasticity; Comparative genomic hybridization; Epithelial–mesenchymal transition; Metastasis; Pancreatic cancer aggressiveness

Mesh:

Year:  2014        PMID: 24837184      PMCID: PMC4198499          DOI: 10.1016/j.molonc.2014.04.007

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  76 in total

1.  Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer.

Authors:  Murali D Bashyam; Ryan Bair; Young H Kim; Pei Wang; Tina Hernandez-Boussard; Collins A Karikari; Robert Tibshirani; Anirban Maitra; Jonathan R Pollack
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

2.  Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer.

Authors:  M M Javle; J F Gibbs; K K Iwata; Y Pak; P Rutledge; J Yu; J D Black; D Tan; T Khoury
Journal:  Ann Surg Oncol       Date:  2007-09-19       Impact factor: 5.344

3.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

4.  Identification of genomic alterations associated with the aggressiveness of pancreatic cancer using an ultra-high-resolution CGH array.

Authors:  Aude Legoffic; Ezequiel Luis Calvo; Marc Barthet; Jean-Robert Delpero; Jean Charles Dagorn; Juan Lucio Iovanna
Journal:  Pancreatology       Date:  2009-04-29       Impact factor: 3.996

5.  Chromosomal abnormalities of adenocarcinoma of the pancreas: identifying early and late changes.

Authors:  Jeanne Kowalski; Laura A Morsberger; Amanda Blackford; Anita Hawkins; Charles J Yeo; Ralph H Hruban; Constance A Griffin
Journal:  Cancer Genet Cytogenet       Date:  2007-10-01

6.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

7.  SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

Authors:  Amanda Blackford; Oscar K Serrano; Christopher L Wolfgang; Giovanni Parmigiani; Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; James R Eshleman; Michael Goggins; Elizabeth M Jaffee; Christine A Iacobuzio-Donahue; Anirban Maitra; John L Cameron; Kelly Olino; Richard Schulick; Jordan Winter; Joseph M Herman; Daniel Laheru; Alison P Klein; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Ralph H Hruban
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

8.  Mesenchymal-like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial-like counterparts.

Authors:  Arkadeep Sinha; David Cherba; Heather Bartlam; Elizabeth Lenkiewicz; Lisa Evers; Michael T Barrett; Brian B Haab
Journal:  Mol Oncol       Date:  2014-05-02       Impact factor: 6.603

9.  BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury.

Authors:  Michael Zeisberg; Jun-ichi Hanai; Hikaru Sugimoto; Tadanori Mammoto; David Charytan; Frank Strutz; Raghu Kalluri
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

10.  Adaptation to culture of human embryonic stem cells and oncogenesis in vivo.

Authors:  Duncan E C Baker; Neil J Harrison; Edna Maltby; Kath Smith; Harry D Moore; Pamela J Shaw; Paul R Heath; Hazel Holden; Peter W Andrews
Journal:  Nat Biotechnol       Date:  2007-02       Impact factor: 54.908

View more
  4 in total

1.  Occult polyclonality of preclinical pancreatic cancer models drives in vitro evolution.

Authors:  Maria E Monberg; Heather Geiger; Jaewon J Lee; Roshan Sharma; Alexander Semaan; Vincent Bernard; Justin Wong; Fang Wang; Shaoheng Liang; Daniel B Swartzlander; Bret M Stephens; Matthew H G Katz; Ken Chen; Nicolas Robine; Paola A Guerrero; Anirban Maitra
Journal:  Nat Commun       Date:  2022-06-25       Impact factor: 17.694

2.  Mesenchymal-like pancreatic cancer cells harbor specific genomic alterations more frequently than their epithelial-like counterparts.

Authors:  Arkadeep Sinha; David Cherba; Heather Bartlam; Elizabeth Lenkiewicz; Lisa Evers; Michael T Barrett; Brian B Haab
Journal:  Mol Oncol       Date:  2014-05-02       Impact factor: 6.603

3.  Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma.

Authors:  Olivera Grbovic-Huezo; Kenneth L Pitter; Nicolas Lecomte; Joseph Saglimbeni; Gokce Askan; Matilda Holm; Jerry P Melchor; Rohit Chandwani; Suhasini Joshi; Caj Haglund; Christine A Iacobuzio-Donahue; Gabriela Chiosis; Tuomas Tammela; Steven D Leach
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-16       Impact factor: 11.205

4.  Identification of the Neurokinin-1 Receptor as Targetable Stratification Factor for Drug Repurposing in Pancreatic Cancer.

Authors:  Iris Beirith; Bernhard W Renz; Shristee Mudusetti; Natalja Sergejewna Ring; Julian Kolorz; Dominik Koch; Alexandr V Bazhin; Michael Berger; Jing Wang; Martin K Angele; Jan G D'Haese; Markus O Guba; Hanno Niess; Joachim Andrassy; Jens Werner; Matthias Ilmer
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.